Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement

Bibliography

• Edwards KM, Dupont WD, Westrich MK, A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994;169:68-76
   PubMed Web of Science ®Google Scholar
• Keitel WA, Cate TR, Couch RB, Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 1997;15(10):1114-22
   PubMed Web of Science ®Google Scholar
• Neuzil K, Zhu Y, Griffin M, Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002;185:147-52
   PubMed Web of Science ®Google Scholar
• Molinari NA, Ortega-Sanchez IR, Messonnier ML, The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25:5086-96
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. Morb Mortal Wkly Rep 2010;59:RR8
   Google Scholar
• Nockleby H, Niccoll A. Risk groups and other target groups – preliminary ECDC guidance for developing influenza vaccination recommendations for the season 2010-11. Euro Surveill 2010;15(12): pii=19525
   Google Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24(8):1159-69
   PubMed Web of Science ®Google Scholar
• Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003;21:1769-75
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention and control of influenza. recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2004;53(RR-06):1-40. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5306a1.htm
   Google Scholar
• Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004;(3). doi: 10.1002/14651858.CD001269.pub2
   Web of Science ®Google Scholar
• de Jong JC, Beyer WE, Palache AM, Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000;61(1):94-9
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Hilbert AK, Bugarini R, An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006;24:3063-5
   PubMed Web of Science ®Google Scholar
• Kojimahara N, Maeda A, Kase T, Yamaguchi N. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. Vaccine 2006;24:5966-9
   PubMedGoogle Scholar
• Ansaldi F, Bacilieri S, Durando P, Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A/H3N2 drifted influenza viruses. Vaccine 2008;26:1525-9
   PubMed Web of Science ®Google Scholar
• Schultze V, D'Agosto V, Wack A, Safety of MF59 adjuvant. Vaccine 2008;26(26):3209-22 40
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19(17-19):2673-80
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Zancolli M, Durando P, Antibody response against heterogeneous circulating influenza virusstrains elicited by MF59- and non-adjuvanted vaccines during seasons with good orpartial matching between vaccine strain and clinical isolates. Vaccine 2010;28(25):4123-9
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colegate AE, Podda A, Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357(9272):1937-43
   PubMed Web of Science ®Google Scholar
• Evison J, Farese S, Seitz M, Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009;48(10):1402-12
   PubMed Web of Science ®Google Scholar
• de Bruijn IA, Nauta J, Gerez L, The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects). Vaccine 2006;24(44-46):6629-31
   PubMed Web of Science ®Google Scholar
• Baldo V, Menegon T, Bonello C, Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001;19(25-26):3472-5
   PubMed Web of Science ®Google Scholar
• Pregliasco F, Mensi C, Serpilli W, Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging 2001;13(1):38-43
   PubMedGoogle Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T, Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet 2007;370(9587):580-9
   PubMed Web of Science ®Google Scholar
• Chu DW, Hwang SJ, Lim FS, Immunogenicity and tolerability of an AS03(A)- adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009;27(52):7428-35
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Gerlach B, Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010;28(7):1740-5
   PubMed Web of Science ®Google Scholar
• Couch RB, Winokur P, Brady R, Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007;25:7656-63
   PubMed Web of Science ®Google Scholar
• Falsey AR, Treanor JJ, Tornieporth N, Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172-80
   PubMed Web of Science ®Google Scholar
• Keitel WA, Atmar RL, Cate TR, Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006;166:1121-7
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Victor JC, Rotthoff JR, Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006;355:2513-22
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization. An Advisory Committee Statement (ACS). Supplementary statement on influenza vaccination: continued use of Fluviral influenza vaccine in the 2000–2001 season. Can Commun Dis Rep 2001;27:1-3
   Google Scholar
• Piedra PA, Gaglani MJ, Kozinetz CA, Trivalent live attenuated intranasal influenza vaccine administered during the 2003–2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007;120:e553-64
   PubMed Web of Science ®Google Scholar
• Rhorer J, Ambrose CS, Dickinson S, Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009;27:1101-10
   PubMed Web of Science ®Google Scholar
• Tuft L. Active immunization against typhoid fever with particular reference to intradermal method. J Lab Clin Med 1931;16:552
   Google Scholar
• Weller TH, Cheever FS, Enders JF. Immunologic reactions following intradermal inoculation of influenza A and B vaccine. Proc Soc Exp Biol Med 1948;67:96-101
   PubMed Web of Science ®Google Scholar
• Boger WP, Liu OC. Subcutaneous and intradermal vaccination with Asiab influenza vaccine. J Am Med Assoc 1957;165:1687-9
   PubMed Web of Science ®Google Scholar
• McCarroll JR, Kilbourne ED. Immunization with Asian-strain influenza vaccine: equivalence of the subcutaneous and intradermal routes. N Engl J Med 1958;259:618-21
   PubMed Web of Science ®Google Scholar
• Klein M, Huang N. The response of infants and children to Asian influenza vaccine administered by intradermal and subcutaneous routes. J Pediatr 1961;58:312-14
   Google Scholar
• McElroy JT, Szwed JJ. Response to intradermal vaccination with A2, Hong Kong variant, influenza vaccine. N Engl J Med 1969;6:1076
   Google Scholar
• Phillips CA, Forsyth BR, Christmas WA, Purified influenza vaccine and serologic responses to varying doses and different routes of immunization. J Infect Dis 1970;122:26-32
   PubMed Web of Science ®Google Scholar
• Foy HM, Sealey L, Cooney MK, Bor E. Efficacy of intradermally administered A2 Hong Kong vaccine. JAMA 1970;213:130
   PubMed Web of Science ®Google Scholar
• Marks MI, Eller JJ. Intradermal influenza immunization. Experience with Hong kong vaccine. Am Rev Respir Dis 1971;103:579-81
   PubMed Web of Science ®Google Scholar
• Brown H, Kasel JA, Freeman DM, The immunizing effect of influenza A/New Jersey/76 virus vaccine administered intradermally and intramuscularly to adults. J Infect Dis 1977;136:S466-71
   PubMed Web of Science ®Google Scholar
• Brooks JH, Criep LH, Ruben FL. Intradermal administration of bivalent and monovalent influenza vaccines. Ann Allergy 1977;39:110-12
   PubMedGoogle Scholar
• Halperin W, Weiss WI, Altman R, A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 and A/Victoria/75: report of a study and review of the literature. Am J Public Health 1979;69:1247-51
   PubMed Web of Science ®Google Scholar
• Herbert FA, Larke RP, Markstad EL. Comparison of responses to influenza A/New Jersey/76-A/Victoria775 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J Infect Dis 1979;140:234-8
   PubMed Web of Science ®Google Scholar
• Kenney RT, Frech SA, Muenz LR, Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351(22):2295-301
   PubMed Web of Science ®Google Scholar
• Auewarakul P, Kositanontn U, Sornsarhapornkul P, Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007;25:659-63
   PubMed Web of Science ®Google Scholar
• Manuel O, Humar A, Chen MH, Immunogenity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant 2007;7:2567-72
   PubMed Web of Science ®Google Scholar
• Chiu SS, Peiris, Chan KH, Immunogeneity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 2007;119:1076-82
   PubMed Web of Science ®Google Scholar
• Sugimura T, Ito Y, Tanamari Y, Improved antibody responses in infants less than 1 year pld using intradermal influenza vaccination. Vaccine 2008;26:2700-5
   PubMed Web of Science ®Google Scholar
• Kunzi V, Klap JM, Seiberling MK, Immunogenity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. Vaccine 2009;27:3561-7
   PubMed Web of Science ®Google Scholar
• Chiu SS, Chan KH, Tu W, Immunogeneity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial. Vaccine 2009;27:4834-7
   PubMed Web of Science ®Google Scholar
• Gelinck LB, van den Bemt BJ, Marijt WA, Intradermal influenza vaccination in immunocompromised patients is immunogenic and feasible. Vaccine 2009;27:2469-74
   PubMed Web of Science ®Google Scholar
• Jo YM, Song JY, Hwang IS, Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. J Med Virol 2009;81:722-7
   PubMed Web of Science ®Google Scholar
• Chuaychoo B, Wongsurakiat P, Nana A, The immunogenity of intradermal influenza vaccination in COPD patients. Vaccine 2010;28:4045-51
   PubMed Web of Science ®Google Scholar
• Nelson R. Influenza vaccine shortage hits the USA. Lancet 2004;362:2075
   Web of Science ®Google Scholar
• Colorado Department of Public Health and Environment. News release, Friday, December 5, 2003: state health officials recommend targeting of remaining flu vaccine. Available from: www.cdphe.state.co.us
   Google Scholar
• Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008;26:3197-208
   PubMed Web of Science ®Google Scholar
• Vankerckhoven V, Van Damme P. Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines. Expert Opin Drug Deliv 2010;7:1109-25
   PubMed Web of Science ®Google Scholar
• Song JM, Kim YC, Barlow PG, Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res 2010;88:244-7
   PubMed Web of Science ®Google Scholar
• Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010;16:915-20
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Yoo DG, Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010;201:190-8
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Yoo DG, Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 2009;27:6932-8
   PubMed Web of Science ®Google Scholar
• Lenz A, Heine M, Schuler G, Romani N. Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest 1993;92:2587-96
   PubMed Web of Science ®Google Scholar
• Nestle FO, Zheng XG, Thompson CB, Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunol 1993;151(11):6535-45. Erratum in: J Immunol 1994;152(1):376
   PubMed Web of Science ®Google Scholar
• Spellberg B. The cutaneous citadel. A holistic view of skin and immunity. Life Sci 2000;67:477-502
   PubMed Web of Science ®Google Scholar
• Flacher V, Bouschbacher M, Verronesse E, Human Langherans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol 2006;177:7959-67
   PubMed Web of Science ®Google Scholar
• Briggs DJ, Banzhoff A, Nicola U, Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embrio cell vaccine or purified Verocell rabies vaccine. Bull World Health Organ 2000;78:693-8
   PubMed Web of Science ®Google Scholar
• Bryan JP, Sjogren MH, Perine PL, Legters LJ. Low-dose intradermal and intramuscolar vaccination against hepatitis B. Clin Infect Dis 1992;14:697-707
   PubMed Web of Science ®Google Scholar
• Redfield RR, Innis BL, Scott RM, Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 1985;254(22):3203-6
   PubMed Web of Science ®Google Scholar
• Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008;7:1201-14
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Cannon J, Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2286-94
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Wilkins K. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007;25:6755-63
   PubMed Web of Science ®Google Scholar
• Beran J, Ambrozaitis A, Laiskonis A, Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009;7:13
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Vets E, Freese R, Seasonal influenza vaccine delivered by intradermal microinjection: a randomized controlled safety and immunogenicity trial in adults. Vaccine 2008;26:6614-19
   PubMed Web of Science ®Google Scholar
• Arnou R, Eavis P, De Juanes Pardo J-R, Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years. Hum Vaccines 2010;6:346-54
   PubMed Web of Science ®Google Scholar
• Holland D, Booy R, De Looze F, Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008;198:650-8
   PubMed Web of Science ®Google Scholar
• Arnou R, Icardi G, De Decker M, Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009;27:7304-12
   PubMed Web of Science ®Google Scholar
• Van Damme P, Arnou R, Kafeja F, Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010;10:134
   PubMed Web of Science ®Google Scholar
• Morelon E, Noble CP, Daoud S, Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine 2010;28(42):6885-90
   PubMed Web of Science ®Google Scholar
• Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009;27(3):454-9
   PubMed Web of Science ®Google Scholar